Gamida Cell Stock Price

-0.08 (-1.52%)
Upgrade to Real-Time
Regular Market


52 Week Range


Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
Canadian Level 1 + USA
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Gamida Cell Ltd GMDA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.08 -1.52% 5.19 15:55:11
Open Price Low Price High Price Close Price Prev Close
5.22 5.15 5.44 5.27
Bid Price Ask Price Spread News
5.16 5.19 0.03 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,048 331,997 $ 5.30 $ 1,759,397 - 3.91 - 15.00
Last Trade Time Type Quantity Stock Price Currency
15:55:11 100 $ 5.19 USD


Draw Mode:

Gamida Cell Ltd Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 307.25M 59.20M 49.46M $ - $ - -1.66 -3.10
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - -

more financials information »

Gamida Cell News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical GMDA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week5.825.844.805.181,074,629-0.63-10.82%
1 Month6.336.414.805.41411,926-1.14-18.01%
3 Months6.777.094.805.97323,838-1.58-23.34%
6 Months8.2015.004.809.01577,301-3.01-36.71%
1 Year3.9715.003.918.54528,5741.2230.73%
3 Years8.3015.412.607.90244,973-3.11-37.47%
5 Years8.3015.412.607.90244,973-3.11-37.47%

Gamida Cell Description

Gamida Cell Ltd is a biopharmaceutical company involved in developing advanced cell therapies with the potential to cure cancer and rare, serious hematologic diseases. The company's product includes NiCord that is a cell therapy based on NAM-expanded cord blood designed to enhance and expand the life-saving benefits of hematopoietic stem cell transplant. It is also developing GDA-201 which is innate immunotherapy of expanded natural killer cells, for the treatment of refractory non-Hodgkin lymphoma and multiple myeloma. It is developing a diverse pipeline of cell therapies using its proprietary NAM technology that has the potential to bring life-saving treatment options to patients.

Your Recent History
Gamida Cel..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.